This is especially relevant for CCR2, that is known to recruit myeloid-derived suppressor cells to the tumour niche, which in turn, promotes tumour growth.112,113 Further clinical trials are required to validate these findings and to determine whether patients responding to BETi show changes in the number of tumour-infiltrating myeloid cells. The gene discussed is CCR2; the disease is neoplasm.